🏛️ Verified NIH Record • Updated 2026-06-18
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease (NCT05910528)
A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Who can join: Review the eligibility criteria below.
Location: Digestive Health Specialists — Dothan, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Digestive Health Specialists — Dothan, Alabama
- Medical Research Center of Connecticut, LLC — Hamden, Connecticut
- I.H.S Health Northwell Health — Kissimmee, Florida
- Brigham and Women's Hospital — Boston, Massachusetts
- Clinical Research Institute of Michigan — Chesterfield, Michigan
- AZ Delta — Roeselare,
- CHU de Nantes — Nantes,
- Institut des MICI, Clinique Ambroise Paré — Neuilly-sur-Seine,
- CHRU de Nancy Brabois — Vandœuvre-lès-Nancy,
- Twoja Przychodnia-Szczecinskie Centrum Medyczne — Szczecin,
- WIP Warsaw IBD Point Profesor Kierkus — Warsaw,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohns Disease
- Oral N-acetylglucosamine in Crohn's Disease — Baltimore, Maryland
- Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation — New York, New York
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Atlanta, Georgia
- Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD — Hamilton, Ontario
- Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy — Rochester, Minnesota
Explore by condition: All Crohns Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.